RecruitingPhase 1NCT07226349

A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors

A Phase 1a/1b, Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-75098 Alone and in Combination With Other Agents in Patients With Advanced Solid Tumors

Sponsor

BeOne Medicines

Enrollment

105 participants

Start Date

Dec 11, 2025

Study Type

INTERVENTIONAL

Conditions

Advanced Solid Tumor

Summary

The purpose of this study is to evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-75098 alone and in combination with BGB-43395 and fulvestrant in participants with advanced solid tumors.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called BG-75098, a drug called BGB-43395, and others for people with advanced solid tumor. The study is currently recruiting participants at 21 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGBG-75098

Administered orally.

DRUGBGB-43395

Administered orally.

DRUGFulvestrant

Administered by intramuscular injection.

Locations(21)

University of Alabama At Birmingham Hospital

Birmingham, Alabama, United States

Yale Cancer Center

New Haven, Connecticut, United States

Sidney Kimmel Comprehensive Cancer At Johns Hopkins

Baltimore, Maryland, United States

The University of Texas Md Anderson Cancer Center

Houston, Texas, United States

Next Houston

Houston, Texas, United States

Medical College of Wisconsin

Milwaukee, Wisconsin, United States

Blacktown Cancer and Haematology Centre

Blacktown, New South Wales, Australia

Genesiscare St Leonards

St Leonards, New South Wales, Australia

Icon Cancer Centre Wesley

Auchenflower, Queensland, Australia

Cabrini Hospital Malvern

Malvern, Victoria, Australia

Peter Maccallum Cancer Centre

Melbourne, Victoria, Australia

One Clinical Research

Nedlands, Western Australia, Australia

Cancer Hospital Chinese Academy of Medical Sciences

Beijing, Beijing Municipality, China

Sun Yat Sen Memorial Hospital, Sun Yat Sen University (South)

Guangzhou, Guangdong, China

Harbin Medical University Cancer Hospital

Harbin, Heilongjiang, China

Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology

Wuhan, Hubei, China

Union Hospital Tongji Medical College Huazhong University of Science and Technologyjinyinhu Branch

Wuhan, Hubei, China

Jiangsu Province Hospital Longjiang Branch

Nanjing, Jiangsu, China

Qilu Hospital of Shandong University

Jinan, Shandong, China

Weifang Peoples Hospital

Weifang, Shandong, China

Rigshospitalet

Copenhagen, Denmark

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07226349

Related Trials

Study of Lunresertib Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors

NCT0485565622 locations

Metformin Combined With Chemotherapy and/or Immunotherapy in Solid Malignancies

NCT0709829910 locations

A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors

NCT057658518 locations

A First-in-Human Study of BG-C0979 in Adults With Advanced Solid Tumors

NCT0741483616 locations

Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors

NCT0697411015 locations